Iovance Biotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Revenue	250.43	164.07	1.19	-	-	-	Upgrade
Revenue Growth (YoY)	175.62%	13698.99%	-	-	-	-	Upgrade
Cost of Revenue	198.61	124	10.76	-	-	-	Upgrade
Gross Profit	51.82	40.08	-9.57	-	-	-	Upgrade
Selling, General & Admin	158.99	153.02	106.92	104.1	83.66	60.21	Upgrade
Research & Development	306.18	282.34	344.08	294.78	259.04	201.73	Upgrade
Operating Expenses	463.15	435.35	450.99	398.88	342.7	261.94	Upgrade
Operating Income	-411.33	-395.28	-460.56	-398.88	-342.7	-261.94	Upgrade
Interest & Investment Income	10.01	10.01	9.44	3.46	6.46	4.22	Upgrade
EBT Excluding Unusual Items	-401.82	-385.27	-451.12	-395.42	-336.24	-257.72	Upgrade
Gain (Loss) on Sale of Investments	8.63	10.26	3.61	-0.47	-6.01	-1.87	Upgrade
Pretax Income	-398.33	-375.01	-447.52	-395.89	-342.25	-259.58	Upgrade
Income Tax Expense	-0.7	-2.83	-3.48	-	-	-	Upgrade
Net Income	-397.63	-372.18	-444.04	-395.89	-342.25	-259.58	Upgrade
Net Income to Common	-397.63	-372.18	-444.04	-395.89	-342.25	-259.58	Upgrade
Shares Outstanding (Basic)	332	290	235	159	153	138	Upgrade
Shares Outstanding (Diluted)	332	290	235	159	153	138	Upgrade
Shares Change (YoY)	19.46%	23.28%	47.64%	3.82%	10.92%	11.23%	Upgrade
EPS (Basic)	-1.20	-1.28	-1.89	-2.49	-2.23	-1.88	Upgrade
EPS (Diluted)	-1.20	-1.28	-1.89	-2.49	-2.23	-1.88	Upgrade
Free Cash Flow	-351.82	-364.05	-384.11	-313.18	-265.52	-251.93	Upgrade
Free Cash Flow Per Share	-1.06	-1.26	-1.63	-1.97	-1.73	-1.82	Upgrade
Gross Margin	20.69%	24.43%	-	-	-	-	Upgrade
Operating Margin	-164.25%	-240.92%	-38734.99%	-	-	-	Upgrade
Profit Margin	-158.78%	-226.84%	-37345.42%	-	-	-	Upgrade
Free Cash Flow Margin	-140.49%	-221.89%	-32305.30%	-	-	-	Upgrade
EBITDA	-375.79	-362.11	-439.14	-389.57	-339.59	-260.8	Upgrade
EBITDA Margin	-150.06%	-220.70%	-	-	-	-	Upgrade
D&A For EBITDA	35.54	33.17	21.42	9.31	3.11	1.14	Upgrade
EBIT	-411.33	-395.28	-460.56	-398.88	-342.7	-261.94	Upgrade
EBIT Margin	-164.25%	-240.92%	-	-	-	-	Upgrade
Revenue as Reported	250.43	164.07	1.19	-	-	-	Upgrade

Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q